ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...

Background: Granulomatous lobular mastitis (GLM) frequently mimics ductal carcinoma in situ (DCIS) in clinical presentation and imaging characteristics, leading to misdiagnosis and unnecessary ...

PEABODY, Mass., Nov. 17, 2025 /PRNewswire/ -- Privo Technologies today announced results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch for ...

Invasive lobular carcinoma accounts for about 10% of breast cancer diagnoses. Its incidence is increasing at the rate of 2.8% annually -- more than triple that of other breast cancers combined. This ...

1Department of Medical Oncology, INSERM CIC 1428, Institut Curie, Paris, France. 2Department of Medicine, Faculty of Medicine, University of Geneva, Geneva ...

Authors say that because survival after seven years is lower, more early detection strategies are needed. HealthDay News — The incidence rates for invasive lobular carcinoma (ILC) increased from 2012 ...

Just weeks after learning she was expecting her fourth child, Stephanie Wysaski felt a lump on her chest. Tests confirmed that she had a breast cancer called invasive lobular carcinoma, which is ...

Lobular breast cancer patients gathered at Fred Hutch Cancer Center last week for a two-hour program featuring patient stories, epidemiological findings and new developments in screening and clinical ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...